ASCO Annual Meeting

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advanced uveal melanoma.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Jedd D. Wolchok, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

Robert Figlin, MD, FACP, discusses the sequencing of mTOR inhibitors and tyrosine kinase inhibitors in renal cell carcinoma.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.

Constance D. Lehman, MD, PhD, Vice Chair, Radiology Department, University of Washington School of Medicine, Medical Director, Imaging, Seattle Cancer Care Alliance, discusses the use of breast MRI.

Robert Andtbacka, MD, from the Huntsman Cancer Institute, provides an overview of the phase III OPTiM trial that explored treatment with talimogene laherparepvecin patients with advanced melanoma.